{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:16:20Z","timestamp":1789031780426,"version":"build-2803163510"},"reference-count":13,"publisher":"Japan Atherosclerosis Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2018]]},"DOI":"10.5551\/jat.40204","type":"journal-article","created":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T22:09:09Z","timestamp":1500588549000},"page":"199-202","source":"Crossref","is-referenced-by-count":34,"title":["Statin Responses in Chinese Patients"],"prefix":"10.5551","volume":"25","author":[{"given":"Brian","family":"Tomlinson","sequence":"first","affiliation":[{"name":"Research Center for Translational Medicine, Shanghai East Hospital Affiliated to Tongji University School of Medicine"},{"name":"Department of Medicine & Therapeutics, The Chinese University of Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Chan","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Min","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Shanghai East Hospital, Tongji University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","unstructured":"1) Naito R, Miyauchi K, Daida H: Racial Differences in the Cholesterol-Lowering Effect of Statin. J Atheroscler Thromb, 2017; 24: 19-25"},{"key":"2","unstructured":"2) Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D: Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther, 2005; 78: 330-341"},{"key":"3","unstructured":"3) Davidson MH: Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opin Drug Saf, 2004; 3: 547-557"},{"key":"4","unstructured":"4) Martin PD, Warwick MJ, Dane AL, Cantarini MV: A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin Ther, 2003; 25: 2215-2224"},{"key":"5","unstructured":"5) Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Wei C, Chen Y, Mosqueda-Garcia R, Ambrose HJ: Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? Eur J Clin Pharmacol, 2015; 71: 341-355"},{"key":"6","unstructured":"6) Gandelman K, Fung GL, Messig M, Laskey R: Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies. Am J Ther, 2012; 19: 164-173"},{"key":"7","unstructured":"7) Lee HK, Hu M, Lui S, Ho CS, Wong CK, Tomlinson B: Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9\/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics, 2013; 14: 1283-1294"},{"key":"8","unstructured":"8) Niemi M: Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther, 2010; 87: 130-133"},{"key":"9","unstructured":"9) Hu M, Tomlinson B: Pharmacogenomics of lipid-lowering therapies. Pharmacogenomics, 2013; 14: 981-995"},{"key":"10","unstructured":"10) DeGorter MK, Tirona RG, Schwarz UI, Choi YH, Dresser GK, Suskin N, Myers K, Zou G, Iwuchukwu O, Wei WQ, Wilke RA, Hegele RA, Kim RB: Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet, 2013; 6: 400-408"},{"key":"11","unstructured":"11) HPS2-THRIVE Collaborative Group: HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J, 2013; 34: 1279-1291"},{"key":"12","unstructured":"12) Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM: Genetic determinants of statininduced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet, 2012; 5: 257-264"},{"key":"13","unstructured":"13) To KK, Hu M, Tomlinson B: Expression and activity of ABCG2, but not ABCB1 or OATP1B1, are associated with cholesterol levels: evidence from in vitro and in vivo experiments. Pharmacogenomics, 2014; 15: 1091-1104"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/25\/2\/25_40204\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,3]],"date-time":"2018-02-03T04:57:13Z","timestamp":1517633833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/25\/2\/25_40204\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.40204","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}